Tenofovir disoproxil fumarate with emtricitabine and rilpivirine hydrochloride

PBAC's latest decision on Tenofovir disoproxil fumarate with emtricitabine and rilpivirine hydrochloride: Recommended with restriction (2011). Considered for treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease.

Eligible population

treatment-naïve HIV patients with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease

Therapy area

Immunology

Line of therapy

Initial treatment, Continuing treatment

Evidence base

RCT

Primary endpoint

virologic response (plasma viral load < 50 HIV-1 RNA copies/mL) at 48 weeks

Key trials

ECHO, THRIVE

Comparator

Atripla (tenofovir disoproxil fumarate with emtricitabine and efavirenz)

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated